Related Experiment Video

Updated: Aug 14, 2026

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia

W J E Tissing1, J P P Meijerink, M L den Boer

  • 1University Hospital Rotterdam/Sophia Children's Hospital, Department of Paediatric Oncology/Hematology, Rotterdam, The Netherlands.

Leukemia
|January 17, 2003
PubMed

Insights

Glucocorticoids (GC) are vital for treating acute lymphoblastic leukemia (ALL), but resistance mechanisms are unclear. This review explores GC sensitivity and resistance pathways in leukemia, focusing on the GC receptor and associated proteins.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Glucocorticoids (GC) are primary treatments for acute lymphoblastic leukemia (ALL).
  • Molecular mechanisms underlying GC sensitivity and resistance in ALL remain poorly understood.
  • Understanding these mechanisms is crucial for improving leukemia treatment outcomes.

Purpose of the Study:

  • To review current knowledge on GC cytotoxicity in leukemia.
  • To elucidate molecular factors influencing GC sensitivity and resistance in ALL.
  • To identify future research directions for optimizing GC therapy in ALL patients.

Main Methods:

  • Literature review of studies on GC mechanisms in leukemia.
  • Analysis of factors affecting GC receptor function, including polymorphisms and chaperones.
  • Evaluation of the role of drug resistance proteins and cellular signaling pathways.

Main Results:

  • GC resistance is influenced by GC receptor variations, splice variants, and regulatory proteins.
  • Multidrug resistance proteins, glutathione, and heat-shock proteins modulate GC efficacy.
  • Transactivation/transrepression of genes like c-myc by GC receptor impacts apoptosis.

Conclusions:

  • GC resistance in ALL is multifactorial, involving receptor status, drug transporters, and signaling pathways.
  • Further research into these molecular mechanisms can guide the development of novel therapeutic strategies.
  • Personalized approaches considering genetic variations may enhance GC treatment effectiveness in ALL.

More Related Videos

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...